// App-Quantinova.ai

10120 : Phase Ib trial of superoxide (SO) dismutase (SOD) mimetic GC4419 to reduce chemoradiotherapy (CRT)-induced oral mucositis (OM) in patients (pts) with oral cavity or oropharyngeal carcinoma (OCC).

Researchers

Presenter

  • Carryn M. Anderson

Principal Investigators

  • Bryan G. Allen

  • Wenqing Sun

  • Sanjiv S. Agarwala

  • Christopher M. Lee

  • Madhavi L. Venigalla

  • Larisa Greenberg

  • Douglas Adkins

  • Yuhchyau Chen

  • Weining Zhen

  • Diane R. Mould

  • Jon Holmlund

  • Jeffrey Mark Brill

  • Stephen T. Sonis

  • John Michael Buatti

Medical Centers

  • University of Iowa Hospitals and Clinics, Iowa City, IA

  • St. Luke's Medical Center, Easton, PA

  • Cancer Care Northwest, Spokane, WA

  • Lakeland Regional Cancer Center, Lakeland, FL

  • Allegheny Gen Hosp, Pittsburgh, PA

  • Washington University School of Medicine and Siteman Cancer Center, St. Louis, MO

  • University of Rochester Medcal Center, Rochester, NY

  • University of Nebraska Medical Center, Omaha, NE

  • Projections Research Inc., Phoenixville, PA

  • Galera Therapeutics, Inc, Malvern, PA

  • BioModels, Boston, MA

Locations

  • United States

Companies

  • Projections Research

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Oropharyngeal carcinoma

  • Mucositis

  • Solid malignancies

Biomarkers

  • Superoxide dismutase

Drug/Treatment

  • GC4419

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT01921426

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved